Item 1.01. Entry into a Material Definitive Agreement.

On February 15, 2013, Aegerion Pharmaceuticals, Inc. (the "Company") obtained the consent of investors constituting the required supermajority under the Amended and Restated Investor Rights Agreement dated as of November 9, 2007, by and among the Company and the investors listed on Schedule I attached thereto (as amended from time to time, the "Investor Rights Agreement"), to amend the Investor Rights Agreement. The amendment adds a new Section 6.16 to the Investor Rights Agreement, which provides for its termination effective as of February 1, 2013.

The description above of the amendment is qualified in its entirety by reference to the full text of the amendment, a copy of which is attached hereto as Exhibit 10.1 and which is incorporated herein by reference.

Item 1.02. Termination of a Material Definitive Agreement.

As described in Item 1.01 of this Current Report on Form 8-K, the Investor Rights Agreement was terminated effective as of February 1, 2013. The information set forth in Item 1.01 is incorporated in this Item 1.02 by reference.

---

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No. Description

10.1 Amendment and Consent Agreement, dated as of February 15, 2013

---